Interferon beta-1b biosimilar (Probiomed)

干扰素β-1b生物类似药 (Probiomed)

Report date: 2022/01/14 13:23:58

Base Information

Drug NameInterferon beta-1b biosimilar (Probiomed)
Drug Alias NameRecombinant human interferon beta- 1b (Probiomed)干扰素β-1b生物仿制药 (Probiomed)rh IFN beta 1b (Probiomed)
ClassificationBiologics > BiosimilarBiologics > Protein drugs > Recombinant protein > Recombinant cytokines
Mechanisms of ActionInterferon alpha/beta receptor agonistsImmunomodulators
TargetsInterferon alpha/beta receptor
Therapy Area/IndicationsMultiple Sclerosis
Global Approved IndicationsMultiple Sclerosis
Approved Indications in ChinaN/A
Original Approved Country/TerritoryMexico
Original Approved Date2006/03/01
Country/TerritoryMexico
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesProbiomed
China Registration ClassN/A

Develop Information

Active CompaniesProbiomed
Inactive CompaniesN/A
Active IndicationsMultiple Sclerosis
Inactive IndicationsN/A

Other Information

ATC CodeL03AB08
Related LinksN/A